Get startedLog in
    Picture of Gilead Sciences logo

    GILD — Gilead Sciences Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Gilead Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:10-K10-K10-K10-K10-K
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line6,2014,5665,6134808,510
    Depreciation
    Amortisation
    Deferred Taxes
    Non-Cash Items2,7605,7182,96410,3052,537
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital489-1,763-2,302-880-3,949
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Taxes Payable
    Other Operating Cash Flow
    Cash from Operating Activities11,3849,0728,00610,82810,018
    Capital Expenditures-579-728-585-523-563
    Purchase of Fixed Assets
    Other Investing Cash Flow Items-2,552-1,738-1,680-2,926-4,230
    Acquisition of Business
    Sale/Maturity of Investment
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-3,131-2,466-2,265-3,449-4,793
    Financing Cash Flow Items-145-173-278-281-440
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-8,877-6,469-5,125-3,433-7,745
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-659746733,906-2,428